Equity · Healthcare
RXRX
NASDAQRecursion Pharmaceuticals (RXRX)
The line runs 3.26 USD on 24 August through 2.52 USD on 20 November, on a scale from 2 to 5. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.6B USD
- Revenue, year to Dec 2025
- 74.7M USD
- EPS, diluted, year to Dec 2025
- −1.44 USD
- 52-week range
- 2.52 USD – 5 USD
- Avg volume
- 1.6M
- Mentions, 30 days
- 7
- Net sentiment
- +0.06
as of Nov 20, 2026
Have Recursion Pharmaceuticals (RXRX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Recursion Pharmaceuticals insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 23 Oct 2025, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 3 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | Borgeson BlakeDirector | Sell | 40,000 | 155K USD |
| 06 Oct 2026 | Borgeson BlakeDirector | Sell | 50,000 | 242K USD |
| 06 Oct 2026 | HERSHBERG ROBERTDirector | Sell | 25,000 | 125K USD |
| 08 Sep 2026 | Khan NajatCEO and President | Sell | 22,408 | 79K USD |
| 01 Sep 2026 | Borgeson BlakeDirector | Sell | 30,000 | 100K USD |
| Sold | 5 open-market sales | 167,408 | $701K |
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Nov 2026 | Hallett DavidChief Scientific Officer | Tax withheld | 26,657 | 85K USD |
| 16 Nov 2026 | Khan NajatCEO and President | Tax withheld | 85,815 | 273K USD |
| 16 Nov 2026 | Taylor Ben RChief Financial Officer | Tax withheld | 25,018 | 80K USD |
| 02 Nov 2026 | Hassan FredDirector | Award | 156,658 | |
| 06 Oct 2026 | HERSHBERG ROBERTDirector | Option exercise | 25,000 | 56K USD |
| 01 Oct 2026 | Dar ZavainDirector | Award | 4,607 | |
| 01 Oct 2026 | Li Dean YDirector | Award | 3,378 | |
| 15 Sep 2026 | Taylor Ben RChief Financial Officer | Tax withheld | 5,396 | 18K USD |
Which funds hold Recursion Pharmaceuticals (RXRX)?
11 of the 45 institutional funds we track reported a Recursion Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 262.3M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 44,745,025 | 184.8M USD | +8.2% |
| Two Sigma Investments | Added | 7,951,077 | 32.8M USD | +137.1% |
| Millennium Management | Added | 4,044,850 | 16.7M USD | +120.5% |
| Citadel Advisors | Added | 2,962,097 | 12.2M USD | +2,205.5% |
| Marshall Wace | Trimmed | 2,070,693 | 8.6M USD | −56.1% |
| Man Group | Held (±25%) | 650,210 | 2.7M USD | −15.1% |
| Balyasny Asset Management | Added | 541,549 | 2.2M USD | +53.1% |
| Point72 Asset Management | New position | 238,435 | 985K USD | |
| AQR Capital Management | Trimmed | 199,562 | 824K USD | −52.7% |
| Bridgewater Associates | Added | 96,596 | 399K USD | +156.4% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
What has been filed or recorded for Recursion Pharmaceuticals (RXRX)?
The filings we hold for Recursion Pharmaceuticals, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 36 shares | 153 USD notional · <0.001% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 94,866 shares | 347K USD notional · 0.015% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 108,434 shares | 391K USD notional · 0.017% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 717,024 shares | 2.8M USD notional · 0.115% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 623,513 shares | 2.5M USD notional · 0.100% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 15,914 shares | 63K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.22 USD | Revenue $19M |
| 30 Sep 2026 | Financials | Total assets | 1.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 905.8M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.25 USD | Revenue $8M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.22 USD | Revenue $6M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.44 USD | Revenue $75M |
| 31 Dec 2025 | Financials | Revenue | 74.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −644.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.44 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.36 USD | Revenue $5M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.41 USD | Revenue $19M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.50 USD | Revenue $15M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.69 USD | Revenue $59M |
What is Reddit saying about Recursion Pharmaceuticals (RXRX)?
Reddit mentioned RXRX 7 times in the 30 days to 21 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 43% read bullish, 0% bearish and 57% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Recursion Pharmaceuticals (RXRX) compare with its price?
Share ↗
Is the Reddit crowd more bullish on Recursion Pharmaceuticals than on the market?
RXRX reads 40% bullish, 12 points below the market (52%). Over 90 days the gap has run from -12 to +35 points.
- RXRX
- 40%
- bullish, 21 Nov
- Market
- 52%
- bullish, all Reddit, 21 Nov
- Gap
- −12 pts
- RXRX against market
Which subreddits are talking about Recursion Pharmaceuticals (RXRX)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 86% | 6 | +0.05 |
| r/investing | 14% | 1 | +0.10 |
What do people ask about Recursion Pharmaceuticals (RXRX)?
What did Recursion Pharmaceuticals shares close at?2.52
Recursion Pharmaceuticals closed at 2.52 USD on 20 Nov 2026, down 5.26% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Recursion Pharmaceuticals’ market cap?1.6B
Recursion Pharmaceuticals is worth 1.6B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Recursion Pharmaceuticals’ revenue?74.7M
Recursion Pharmaceuticals reported revenue of 74.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Recursion Pharmaceuticals insiders bought or sold shares recently?5 sales
In the 90 days to 22 Nov 2026, Recursion Pharmaceuticals insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 23 Oct 2025, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Recursion Pharmaceuticals?11 of 45
11 of the 45 funds we track reported a Recursion Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Two Sigma Investments and Millennium Management. See Funds
When did Recursion Pharmaceuticals last report earnings?−0.22
Recursion Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.22 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Recursion Pharmaceuticals?5 mentions
Recursion Pharmaceuticals was mentioned 5 times in the last 7 days across the finance subreddits we track, and 7 times over the trailing 30 days. Of the 7 mentions scored for sentiment, 43% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words